Ocular Therapeutix™ Reports First Quarter 2024 Results
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for
Pioneering Medical Innovations
Menu
Pioneering Medical Innovations
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality
Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., – August 15, 2023 – Instylla, Inc., a privately
NEWS PROVIDED BY TiE Global TiE Global Angels, led by TiE Boston, Invests $1.395M as part of a $20M Investment
Sealonix, a Bedford, MA-based developer of sealant products for abdominopelvic and orthopedic procedures, closed a $20m Series A financing.
Proceeds to accelerate commercialization and pipeline expansion of novel FLASH™ Aorto-Ostial Angioplasty System CAMPBELL, Calif., – Ostial Corporation (Ostial), a private medical
BEDFORD, Mass., Dec. 7, 2022 /PRNewswire/ — Rejoni announced today that it has closed a $25 million Series B financing. The round was led by Catalyst Health Ventures, with continued support from Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures, and Iyengar Capital Partners.
Truvic CEO Mike Buck (left) with Imperative Care chairman and CEO Fred Khosravi (right). Credit: Business Wire. The funds will